Why is Caris Life Sciences (CAI) stock up today?

Caris Life Sciences stock climbed from a previous close of $16.45 to $20.00 today — a gain of roughly 21.58% — after the company reported second-quarter 2026 results that included record revenue and volume, and broke even on earnings per share (EPS of $0.00) against an analyst estimate of −$0.017. The break-even result signals the company is closing in on profitability, a milestone that typically draws strong buying interest in growth-stage biotech and medtech names.

The move was further powered by a guidance raise: Caris lifted its full-year 2026 revenue outlook from a range of $1.000B–$1.020B to $1.030B–$1.040B, sitting above the prior consensus estimate of $1.003B. Higher-than-expected forward guidance tends to prompt investors to revise their valuation models upward, which can sharply accelerate buying pressure — particularly in a name that had already fallen roughly 47% from prior highs, creating a compressed starting point.

Analyst reaction reinforced the momentum. Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating on the stock and raised his price target from $25 to $26, citing conviction in the company's trajectory. On the same day, Caris published research alongside ECOG-ACRIN and NRG Oncology demonstrating a multimodal AI approach to predict late distant recurrence risk in HR+ early breast cancer — adding a clinical credibility headline to an already positive earnings day.

The broader market provided no tailwind: the S&P 500 dipped 0.18% and the Nasdaq 100 (QQQ) fell 0.37% on the day, meaning Caris's gain was entirely driven by its own company-specific news rather than a rising tide. The medtech sector saw divergent action — peer BillionToOne fell 38% on the same day, underscoring that today's move in Caris was company-specific rather than sector-wide.

As of the close of trading today, Caris Life Sciences holds a market cap of approximately $5.65B and trades at $20.00, within a day range of $17.94–$20.11. The next scheduled catalyst is the Q3 2026 earnings report, estimated for November 4, 2026.